

## Nplate® (romiplostim) – Expanded indication

- On December 14, 2018, <u>Amgen announced</u> the FDA approval of <u>Nplate (romiplostim)</u>, for the
  treatment of pediatric patients 1 year of age and older with immune thrombocytopenia (ITP) for at
  least 6 months who have had an insufficient response to corticosteroids, immunoglobulins, or
  splenectomy.
  - Nplate was previously approved for the treatment of adult patients with chronic ITP who
    have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.
  - Nplate is not indicated for the treatment of thrombocytopenia due to myelodysplastic syndrome or any cause of thrombocytopenia other than chronic ITP.
  - Nplate should be used only in patients with ITP whose degree of thrombocytopenia and clinical condition increases the risk for bleeding.
  - Nplate should not be used in an attempt to normalize platelet counts.
- ITP is a rare, serious autoimmune disease characterized by low platelet counts in the blood and impaired platelet production. In the U.S., the estimated prevalence of ITP in children is 5.3 per 100,000 children annually. The treatment goal for children with ITP is to achieve and maintain a platelet count that reduces the risk of bleeding.
- The expanded indication for Nplate was based on data from two placebo-controlled studies in pediatric patients. In the first study (phase 3), efficacy was measured by the proportion of patients achieving a durable platelet response and the proportion of patients achieving an overall platelet response (defined as a durable or transient platelet response). In the second study (phase 1/2), efficacy was measured by the proportion of patients who achieved a platelet count of ≥ 50 × 10<sup>9</sup>/L for 2 consecutive weeks and by the proportion of patients who achieved an increase in platelet count of ≥ 20 × 10<sup>9</sup>/L above baseline for 2 consecutive weeks.
  - In the first study, durable platelet response was achieved in 52% and 10% of patients in the Nplate and placebo arms, respectively. Overall platelet response was achieved in 71% and 20% of patients in the Nplate and placebo arms, respectively (p < 0.05 for both).</p>
  - Of the 17 patients who received Nplate in the second study, 15 achieved a platelet count of ≥ 5 × 10<sup>9</sup>/L for 2 consecutive weeks (88.2%, 95% CI: 63.6%, 98.5%). The same 15 patients also achieved an increase in platelet count of ≥ 20 × 10<sup>9</sup>/L above baseline for 2 consecutive weeks during the treatment period. None of the patients treated with placebo achieved either endpoint.
- The recommended initial dose of Nplate is 1 mcg/kg in pediatric patients with ITP. Actual body
  weight at initiation of treatment should always be used when calculating initial dose.
  - Future dose adjustments are based on changes in platelet counts and changes in body weight. Reassessment of body weight is recommended every 12 weeks.
  - Refer to the Nplate drug label for additional dosing information for pediatric and adult patients.



## optumrx.com

OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at **optum.com**.

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.